Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioInvent International has signed a deal with Bayer HealthCare related to the discovery and development of antibody products.
Subscribe to our email newsletter
Under the terms of the agreement, Bayer HealthCare will have a non-exclusive research licence for the use of BioInvent’s proprietary n-CoDeR library for the discovery of human monoclonal antibodies. BioInvent, in addition to its n-CoDeR technology, will provide at BioInvent access to an extended antibody technology suite including BioInvent’s proprietary selection processes, streamlined robotics and Immunoglobulin transient expression technology. Bayer HealthCare will fund all such activities.
As well as undisclosed license fees, BioInvent will receive additional milestone payments and escalating royalties on sales of any products commercialized. The agreement allows for up to 14 antibody products to be developed.